Future Science Group
Browse
Supple_Figure_2.tiff (2.26 MB)
Download file

Suppl_Figure_2: Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma.tiff

Download (2.26 MB)
figure
posted on 2021-08-20, 12:32 authored by Saaya Tsutsué, Shinichi Makita, Jingbo Yi, Bruce Crawford

Supplemental Figure 2 - Claims between 1st March and 30th June 2019 for the pre-COVID-19 subgroup were analyzed in comparison with claims between 1st March and 30th June 2020 for the post-COVID-19 subgroup

Funding

Celgene KK

Brystol Myers Squibb Company

History

Usage metrics

    Future OncologyFuture Oncology

    Categories

    Keywords

    relapserefractoryDiffuse Large B-cell LymphomaSalvage Chemotherapyretrospectivedatabase studycostCOVID-19JapaneseCancer Therapy (excl. Chemotherapy and Radiation Therapy)

    Licence

    CC BY-NC-ND 4.0

    Exports